In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAME: Venclexta (AbbVie)
- INDICATIONS: Chronic lymphocytic leukemia in patients with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy
- CLASS: BCL-2 inhibitor
- HALF-LIFE: 26 hours
- FDA APPROVAL DATE: 04/11/2016
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amiodarone, Azithromycin, Bosentan, Captopril, Carbamazepine, Carvedilol, Ciprofloxacin, Clarithromycin, Conivaptan, Cyclosporine, Digoxin, Diltiazem, Dronedarone, Efavirenz, Erythromycin, Etravirine, Everolimus, Felodipine, Fluconazole, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Live vaccines, Lopinavir, Modafinil, Nafcillin, Phenytoin, Posaconazole, Quercetin, Quinidine, Ranolazine, Rifampin, Ritonavir, Sirolimus, St John's Wort, Stong or moderate P-gp inhibitors or substrates, Strong or moderate CYP3A inducers or inhibitors, Telaprevir, Ticagrelor, Verapamil, Voriconazole - PREGNANCY: May cause fetal harm
Concomitant use of strong CYP3A inhibitors during initiation and ramp-up phase is contra-indicated.
Please login to view the rest of this drug profile.
Page last updated 02/27/2024
